ENGLEWOOD, Colo., April 2, 2020 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue
development stage biopharmaceutical company focused on the
development of immunology based therapies to treat prevalent
inflammatory conditions announced today that it was featured on a
FOX segment titled, "Englewood pharmaceutical company looking to
treat COVID-19 patients with anti-inflammatory drug," reported by
an affiliated television station in Denver, Colorado. The primary cause of death
associated with SARS-Cov-2 ("COVID-19") infection is Acute
Respiratory Distress Syndrome ("ARDS"), and there are no approved
treatments for ARDS or COVID-19. The segment featured the Company's
application to the FDA to study the treatment of COVID-19 induced
ARDS with nebulized Ampion.
To view the FOX video segment in its entirety please visit the
link below. Additional information about the potential suitability
of the anti-inflammatory properties of Ampion being used for this
clinical indication (ARDS) is included in a companion white paper
summary titled, "Rationale and scientific evidence for the
use of Ampion in the treatment of Acute Respiratory Distress
Syndrome secondary to SARS-COV-2," provided in the link
below.
-
https://kdvr.com/news/coronavirus/englewood-pharmaceutical-company-looking-to-treat-covid-19-patients-with-anti-inflammatory-drug/
-
https://ampiopharma.com/wp-content/uploads/2020/04/01-Apr-2020-Ampion-SARS-COV-2-and-ARDS-Flyer_v4.pdf
Michael Macaluso, Ampio CEO,
noted "The Company is exploring options that may enable the
completion of the AP-013 study, our Phase 3 clinical trial for the
treatment of severe osteoarthritis of the knee, during this
COVID-19 pandemic. Simultaneously, we have directed our R&D
efforts to explore the possible application of the immunomodulatory
and anti-inflammatory properties of Ampion in the most severe and
lethal complication of the COVID-19 infected patients: ARDS. The
FDA has been very responsive, and the Company is grateful for the
Agency's efforts as we work together to study the potential
benefits of Ampion in this population."
Enquiries from health professionals and media should be directed
via email to mmacaluso@ampiopharma.com
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage
biopharmaceutical company primarily focused on the development of
Ampion, our product candidate, to treat prevalent inflammatory
conditions for which there are limited treatment
options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2032, and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the biologics
price competition and innovation act (BPCIA).
Forward-Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "believe,"
"expect," "plan," "anticipate," and similar expressions. These
forward-looking statements include statements regarding Ampio's
expectations with respect to Ampion™ and its classification,
as well as those associated with regulatory approvals and other FDA
decisions, the Biological License Application (BLA), the ability of
Ampio to enter into partnering arrangements, clinical
trials and decisions and changes in business conditions and similar
events, the ability to receive regulatory approval to conduct
clinical trials, that Ampion may be used to treat ARDS induced by
COVID-19, all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include those
detailed from time to time in Ampio's filings with the Securities
and Exchange Commission, including without limitation, under
Ampio's Annual Report on Form 10-K and other documents filed with
the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company Contact
Dan
Stokely, CFO
Phone: (720) 437-6500
info@ampiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-application-to-the-fda-for-a-clinical-study-of-ampion-to-treat-covid-19-induced-acute-respiratory-distress-syndrome-ards-featured-in-fox-news-video-301034091.html
SOURCE Ampio Pharmaceuticals, Inc.